TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants Achieving Predefined Antibody Response to Target Antigens at Day 29
Endpoint domain: Physiological/clinical
Primary endpoint: Keloid Formation at Site of Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Pigmentation Changes at Site of Injection
Endpoint domain: Adverse events/effects
Primary endpoint: Number of flat polyps per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: safety measures
Endpoint domain: Adverse events/effects
Primary endpoint: efficacy measures
Endpoint domain: Physiological/clinical
Primary endpoint: Adenoma recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Platelet Alpha Thrombin PAR-1 Receptor Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bronchiolitis obliterans Syndrome (BOS) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Intraepithelial Neoplasia (IN) Detection Rate (True Positive Findings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraepithelial Neoplasia (IN) Detection Rate (False Positive Findings)
Endpoint domain: Adverse events/effects
Primary endpoint: Intraepithelial Neoplasia (IN) Detection Rate (True Negative Findings)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Intraepithelial Neoplasia (IN) Detection Rate (False Negative Findings)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in BGSI Goal Attainment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of postoperative pulmonary complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Ghent University Scoring System (GUSS) of Target Joints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of events remembered
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants With Clinical Benefit of CR, PR, or Stable Disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma and cerebrospinal fluid drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Random plasma and cerebrospinal fluid drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough plasma and cerebrospinal fluid drug concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Responders in Midface Fullness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montreal Cognitive Assessment (MoCA) test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in pain after 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in pain while walking at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolic syndrome component detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: isolated Nodal Recurrences
Endpoint domain: Mortality/survival
Primary endpoint: Change in fasting high sensitivity C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Eyes With Graded Slit Lamp Findings Greater Than Grade 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of New Nosocomial Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Range of Motion values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pDC Content of the Graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Allergic Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Euploidy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mosaicism rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anatomical improvement according to POP-Q Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change (CGIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Participants With AEs Leading to TCZ Discontinuation, Interruption, or Dose Modification
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinically Significant Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of acute and chronic GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: 12-Month Binary MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 12-month Composite Safety Endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Repeat Revascularization (PCI and/or CABG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Daily OFF-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) in single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve (AUC) in single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: redox state of thiol-disulfide pools
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: global metabolic spectrum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma nitrite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of DW (in kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sibling relationship quality
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Best Tumor Response (Core)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Best Tumor Response (Core + Extension)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: muscle oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in the Number of Eosinophils Per High Power Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intra- and postoperative intra-ocular bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: ka
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo dissolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancouver Obsessional Compulsive Inventory - checking subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average time spent checking per week
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in UPDRS part III score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of SCCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of Recurrent Thrombosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Geometric Mean Antibody Titres for Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Seropositive Subjects for Haemagglutination Inhibition (HI) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Phagocytic activity of blood platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for unscheduled medical attention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Satisfaction with ToR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effectiveness of Fenretinide + Tamoxifen in treating breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Erectile function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants with pregnancy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Incidence of everolimus-induced interstitial lung disease (ILD)
Endpoint domain: Adverse events/effects
Primary endpoint: Venous thromboembolism incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total volume of new ischemic cerebral lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of Communication and Decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Bacterial Quantity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Y-90 distribution and concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with HBV DNA <15 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematocrit Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Change in Cellulite Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Fecal Occult Blood Test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of Chronic Non-Malignant Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diabetes type defined by insulin requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to inhibitor formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to inhibitor eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mass balance recovery of total radioactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and structural identification of metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of VTE and VTE-related mortality
Endpoint domain: Mortality/survival
Primary endpoint: Traumatic Brain Injury-Quality of Life Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Successful discontinuation of medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Cerebrospinal Fluid Amyloid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Composite Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects with Adverse Events related to study drug
Endpoint domain: Adverse events/effects
Primary endpoint: change in blood oxygenation (PaO2/FIO2 ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Post mastectomy pain syndrome (PMPS)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Raynaud's Condition Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene alteration assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Pathologic Complete Response (pCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side Effects of Weekly Nab-paclitaxel, Carboplatin and Bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of change in tongue area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of Total Glycosaminoglycan (GAG) in CSF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic Joint Classification System outcome measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: blood miRNA signatures predictors of bevacizumab response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major molecular response to imatinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway-specific safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: General safety and tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: subclinical atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ability to interpret medical statistics
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Proportion of patients with plaque disruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Specific survival to 10 years
Endpoint domain: Mortality/survival
Primary endpoint: Degree of functional disability associated with lumbar pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood flow response to Acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postprandial concentration of glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients That Tolerated Propranolol
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Estrogen Metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients meeting physical activity recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 3D-US volume measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and Proportion of Subjects Experiencing Device Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Change in AZ Bio Sentence Score in Noise
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HDRS-21 Score Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects experiencing Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects experiencing Dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Local tolerability issues
Endpoint domain: Adverse events/effects
Primary endpoint: Predictive values of Cytomegalovirus infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MMR (BCR/ABL IS < 0.01)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in the mandibular volume and superficial area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the condylar volume and superficial area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the mandibular body (Go-Gn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Out of Pocket Expenditure for Surgical Care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LUTS (Lower Urinary Tract Symptoms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prevalence rates of involuntary treatment episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Biochemically Validated Continuously Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement in perfusion as measured by ankle-brachial index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Behavior assessments
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Parenting Young Children Scale (Supporting Positive Behaviour subscale; Setting Limits subscale)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Sinovuyo Observational Coding System
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Urine Albumin/Creatinine ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinical-microbiological cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of resistance to fosfomycin
Endpoint domain: Adverse events/effects
Primary endpoint: New composite vascular event 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: New composite vascular event 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MSI status in blood sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Factor levels as percent of normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Inhibitor titers in Bethesda Units (BU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 12 Month Overall Survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in Activity units
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First call for rescue analgesia
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Concussive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to Cut-off Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Seroconverted Subjects With RV Antibody Concentrations Above or Equal to 20 U/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-RV IgA Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Urine Total Nicotine Equivalent (TNE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of gastrointestinal symptoms associated with Celiac Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequencies of wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Six Minute Walking Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative amount of mineralised tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Delay before expertise by a dermatologist
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Olerud-Molander ankle function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Response rate after first induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate complete remissions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of PMV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peri-implanter sulcus fluid levels of RANKL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peri-implanter sulcus fluid levels of OPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Free of hospital admissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change from baseline Montgomery Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: volume of residual intrastent mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient and physician-assessed degree of tremors based on Fahn-Tolosa-Marin Tremor Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient and physician-assessed degree of tremors based on Quality of Life in Essential Tremor (QUEST) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Scores on Quality of Life in Essential Tremor Questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Repeat HIV Testing
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: toxicity according to RTOG criteria
Endpoint domain: Adverse events/effects
Primary endpoint: post-menstrual spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Short-term disease progression in terms of motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Short-term disease progression in terms of cognitive functioning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Mid-term disease progression in terms of motor symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes